![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, May 07, 2024 7:03:27 AM
Recent ELDN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 09:00:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 09:00:03 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 06/06/2024 08:01:40 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 06/06/2024 04:15:15 AM
- Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation • GlobeNewswire Inc. • 06/03/2024 08:01:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/30/2024 08:05:22 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/24/2024 08:02:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 11:00:37 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 08:30:23 PM
- Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress • GlobeNewswire Inc. • 05/09/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 11:15:13 AM
- Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection • GlobeNewswire Inc. • 05/07/2024 11:05:00 AM
- Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement • GlobeNewswire Inc. • 05/07/2024 11:00:00 AM
- Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results • GlobeNewswire Inc. • 03/28/2024 08:01:00 PM
- Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection • GlobeNewswire Inc. • 03/25/2024 08:56:42 PM
- Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human • GlobeNewswire Inc. • 03/21/2024 02:31:12 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:35:28 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 08:01:53 PM
- Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 02/14/2024 12:01:00 AM
- Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook • GlobeNewswire Inc. • 01/04/2024 09:40:44 PM
- Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 12/04/2023 11:00:00 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM